专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5922587A Phospholipid dependent prothrombin activator obtained from snake venom 失效
标题翻译：从蛇毒获得的磷脂依赖性凝血酶原激活物
公开(公告)号：US5922587A
公开(公告)日：1999-07-13
申请号：US472005
申请日：1995-06-06
申请人： Douglas A. Triplett , Kurt Stocker
发明人： Douglas A. Triplett , Kurt Stocker
IPC分类号： A61K35/58 , A61P7/04 , C07K14/46 , C12N9/64 , C12Q1/56 , G01N33/53 , C12N9/48 , C12N9/74
CPC分类号： C12Q1/56 , C07K14/46 , C12N9/6418 , G01N2333/4613 , G01N2333/4633 , G01N2333/4646 , G01N2405/04
摘要： It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyuranus and Psuedonaja genera is most useful in tests for the determination of Lupus Anticoagulant. Based on this, several clotting, chromogenic and immunochromogenic tests have been developed.
摘要翻译：已经发现，使用从属于Elapidae家族的蛇，特别是Oxyuranus和Psuedonaja属的蛇的毒液中纯化的磷脂依赖性凝血酶原激活物在测定狼疮抗凝剂的测试中是最有用的。基于此，已经开发了几种凝血，显色和免疫荧光测试。

2. 发明申请

US20070275902A1 Treatment of Phosphatidylinositol Phospholipid Disorders 审中-公开
标题翻译：磷脂酰肌醇磷脂疾病的治疗
公开(公告)号：US20070275902A1
公开(公告)日：2007-11-29
申请号：US10580302
申请日：2004-11-23
申请人： Matthew Gonda , Vernon Alvarez , Carol Grimes
发明人： Matthew Gonda , Vernon Alvarez , Carol Grimes
IPC分类号： A61K38/08 , A61K38/02 , A61P35/00 , A61P35/02 , C12N5/06 , C12N5/08 , G01N33/574
CPC分类号： G01N33/92 , A61K38/17 , G01N33/5011 , G01N2333/4613
摘要： Disclosed is a method of treating cell proliferative disorders, such as cancer, with amounts of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to phosphoinositol phospholipids.
摘要翻译：公开了一种治疗细胞增殖性疾病如癌症的方法，其量可以与磷酸肌醇磷脂结合有效的氯毒素和/或其衍生物，类似物或片段的量。

3. 发明授权

US5705198A Test for lupus anticoagulant 失效
标题翻译：测试狼疮抗凝剂
公开(公告)号：US5705198A
公开(公告)日：1998-01-06
申请号：US471796
申请日：1995-06-06
申请人： Douglas A. Triplett , Kurt Stocker
发明人： Douglas A. Triplett , Kurt Stocker
IPC分类号： A61K35/58 , A61P7/04 , C07K14/46 , C12N9/64 , C12Q1/56 , G01N33/53
CPC分类号： C12Q1/56 , C07K14/46 , C12N9/6418 , G01N2333/4613 , G01N2333/4633 , G01N2333/4646 , G01N2405/04
摘要： It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyaranus and Psuedonaja genera is most useful in tests for the determination of Lupus Anticoagulant. Based on this, several clotting, chromogenic aria immunochromogenic tests have been developped.
摘要翻译：已经发现，使用从属于Elapidae家族的蛇，特别是Oxyaranus和Psuedonaja属的蛇的毒液中纯化的磷脂依赖性凝血酶原激活物在测定狼疮抗凝剂的测试中是最有用的。基于此，已经开发了几种凝血，发色咏叹调免疫荧光测试。

4. 发明授权

US11680947B2 Marker polypeptide of bothrops atrox-like thrombin and method thereof for detecting species source and content of snake venom-like thrombin and application 有权
公开(公告)号：US11680947B2
公开(公告)日：2023-06-20
申请号：US17932301
申请日：2022-09-15
申请人： Shandong Institute for Food and Drug Control , Penglai Nuokang Pharmaceutical Co., Ltd.
发明人： Feng Shi , Weijian Wang , Ruiqing Xian , Liping Gong , Congcong Wang , Baojian Hang , Jing Dong , Honghai Li
IPC分类号： G01N33/68 , G16C20/20
CPC分类号： G01N33/6848 , G16C20/20 , G01N2333/4613 , G01N2333/745 , G01N2800/42
摘要： Disclosed are specifically a marker polypeptide of a Bothrops atrox-like thrombin and a method thereof for detecting species source and content of a snake venom-like thrombin and an application, relating to the technical field of snake venom detection. An amino acid sequence of the marker polypeptide is EAYNGLPAK (SEQ ID NO:1), and the marker polypeptide may be used to detect the species source and content of the snake venom-like thrombin in a sample. The marker polypeptide of the present disclosure may play an important role in characterizing the species source and content of the snake venom-like thrombin in the sample, and fill in the blank of a quality standard of snake venom of the Bothrops atrox.

5. 发明授权

US5846755A Method for determining the therapeutic activity of metalloproteinase inhibitor compounds 失效
标题翻译：确定金属蛋白酶抑制剂化合物治疗活性的方法
公开(公告)号：US5846755A
公开(公告)日：1998-12-08
申请号：US693021
申请日：1996-08-06
申请人： Vencenzo Politi , Silvana D'Alessio , Giovanni Di Stazio , Giovanna De Luca , Mario Materazzi
发明人： Vencenzo Politi , Silvana D'Alessio , Giovanni Di Stazio , Giovanna De Luca , Mario Materazzi
IPC分类号： C12N9/99 , A61K35/58 , A61K38/00 , A61K45/00 , A61P9/10 , A61P11/00 , A61P25/30 , A61P37/00 , A61P43/00 , C07K5/02 , C07K5/06 , C07K5/065 , C07K5/097 , C12Q1/37
CPC分类号： C12Q1/37 , C07K5/0202 , C07K5/0205 , C07K5/06043 , C07K5/0606 , C07K5/06078 , C07K5/06191 , C07K5/0821 , A61K38/00 , G01N2333/4613 , G01N2333/462 , G01N2333/78 , G01N2333/96486
摘要： A method for determining the therapeutic potential of peptidomimetic compounds as inhibitors of zinc-dependent metalloproteinase activity associated with pathological conditions of humans and animals.
摘要翻译：用于确定拟肽化合物作为与人和动物的病理状况相关的锌依赖性金属蛋白酶活性的抑制剂的治疗潜力的方法。

6. 发明授权

US5472851A Method of determining a plasminogen activator and its inhibitor 失效
标题翻译：测定纤溶酶原激活物及其抑制剂的方法
公开(公告)号：US5472851A
公开(公告)日：1995-12-05
申请号：US698314
申请日：1991-05-10
申请人： Genevieve Pussard nee Contant , Jean-Luc Martinolli , Gerad Quentin
发明人： Genevieve Pussard nee Contant , Jean-Luc Martinolli , Gerad Quentin
IPC分类号： C12Q1/37 , C12Q1/56 , A01N37/18 , C12N9/72 , C12P21/06
CPC分类号： C12Q1/56 , G01N2333/4613 , G01N2333/81 , G01N2333/8132 , G01N2333/9726
摘要： The present invention relates to the use of a substance which inhibits the plasma proteins .alpha..sub.2 -AP and/or .alpha..sub.2 -M in the field of the determination and assay of plasminogen activators and inhibitors of said plasminogen activators. It relates in particular to a method of determining (i) a plasminogen activator selected from the group consisting of tissue plasminogen activators (tPAs) and urokinase plasminogen activators (uPAs), and (ii) an inhibitor (PAI) of said plasminogen activator, said method, which involves converting plasminogen to plasmin and then assaying the plasmin resulting from said conversion, comprising inhibition of the plasma proteins .alpha..sub.2 -antiplasmin and/or .alpha..sub.2 -macroglobulin by means of a substance selected from the group consisting of metalloproteinase materials.
摘要翻译：本发明涉及抑制血浆蛋白α2 -AP和/或α2 -M的物质在纤溶酶原激活剂和所述纤溶酶原激活物的抑制剂的测定和测定领域中的应用。特别涉及确定（i）选自组织纤溶酶原激活剂（tPA）和尿激酶纤溶酶原激活剂（uPA）的纤溶酶原激活剂的方法，和（ii）所述纤溶酶原激活剂的抑制剂（PAI），所述方法，其涉及将纤溶酶原转化为纤溶酶，然后测定由所述转化产生的纤溶酶，包括通过选自金属蛋白酶材料的物质抑制血浆蛋白α2-抗血纤维蛋白和/或α2-巨球蛋白。

7. 发明授权

US06936423B1 Anti-LTNF for in vitro assay of biological toxins 失效
标题翻译：抗LTNF用于体外测定生物毒素
公开(公告)号：US06936423B1
公开(公告)日：2005-08-30
申请号：US09300612
申请日：1999-04-27
申请人： Binie V. Lipps , Frederick W. Lipps
发明人： Binie V. Lipps , Frederick W. Lipps
IPC分类号： A61K38/10 , C07K7/08 , C07K14/47 , G01N33/53 , G01N33/569
CPC分类号： G01N33/5308 , G01N2333/315 , G01N2333/33 , G01N2333/43521 , G01N2333/4613 , Y10S530/829 , Y10S530/83
摘要： Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the first fifteen amino acids of LTNF-n is: Leu Lys Ala Met Asp Pro Thr Pro Pro Leu Trp Ile Lys Thr Glu. Antibodies to LTNF-n and synthetic peptides consisting of fifteen, ten and five amino acids from the N-terminal of the above sequence, designated as LTNF-15, LTNF-10 and LTNF-5 were produced by immunizing Balb/C mice to produce Anti-LTNF-n, Anti-LTNF-15, Anti-LTNF-10 and Anti-LTNF-5. The anti LTNF-n, anti-LTNF-15, anti-LTNF-10 and anti-LTNF-5 react immunologically with all types of toxins derived from animal, plant and bacteria and can be assayed by immunological in vitro test such as ELISA tests. Anti-LTNFs react roughly proportional to lethal dose of biological toxins under in vitro immunological ELISA test similar to the mouse bioassay test. This property of anti-LTNFs can be utilized to replace the use of animals for bioassay of toxins from animal, plant and bacteria. Anti-LTNFs can be polyclonal raised in animals or monoclonal made in hybridomas. Anti-LTNFs can be used in crude form for immunological in vitro testing. However, purified IgG from the anti LTNFs is most desirable for consistent results from the in vitro tests. In general, the in vitro use of Anti-LTNFs is a replacement for animal use as is currently required for the assay of biological toxins.
摘要翻译：致死毒素中和因子已经通过高压液相色谱（HPLC）分级从负鼠血清中纯化出来。来自LTNF-n的前15个氨基酸的N-末端的氨基酸序列是：Leu Lys Ala Met Asp Pro Thr Pro Pro Leu Trp Ile Lys Thr Glu。通过免疫Balb / C小鼠产生LTNF-n的抗体和由上述序列的N末端组成的15个，10个和5个氨基酸的合成肽，称为LTNF-15，LTNF-10和LTNF-5，产生抗LTNF-n，抗LTNF-15，抗LTNF-10和抗LTNF-5。抗LTNF-n，抗LTNF-15，抗LTNF-10和抗LTNF-5与来源于动物，植物和细菌的所有类型的毒素进行免疫反应，并且可以通过免疫学体外测试如ELISA测试。类似于小鼠生物测定试验，抗LTNFs在体外免疫ELISA测试下与生物毒素的致死剂量大致成比例。抗LTNF的这种性质可以用于替代动物用于生物测定来自动物，植物和细菌的毒素的使用。抗LTNFs可以在动物中产生多克隆或在杂交瘤中制成单克隆抗体。抗LTNF可以粗制形式用于免疫体外测试。然而，来自抗LTNF的纯化的IgG对于来自体外测试的一致结果是最理想的。一般来说，抗LTNF的体外应用是目前生物毒素测定所需的动物用途的替代物。

8. 发明授权

US6051434A Activated protein C resistance test 失效
标题翻译：活化蛋白C电阻测试
公开(公告)号：US6051434A
公开(公告)日：2000-04-18
申请号：US776897
申请日：1997-04-24
申请人： Thomas Exner
发明人： Thomas Exner
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2333/4613 , G01N2333/4616 , G01N2333/96444 , G01N2333/96461 , G01N2333/96463 , Y10T436/25
摘要： The method for determining functional activity of protein C in a human plasma sample includes incubating the human plasma sample with exogenous reagents that activate factor V and a common pathway of the blood coagulation mechanism through factor X, with activated exogenous protein C and with components that are necessary for efficient clotting of the human plasma sample, or incubating the human plasma sample with exogenous reagents that induce the presence of thrombin in a factor V dependent manner, with activated exogenous protein C and with components that are necessary for efficient clotting of the human plasma sample; monitoring a reaction indicative of a potential rate of coagulation of the plasma sample and comparing the resulting potential rate of coagulation with an equivalent rate for normal patient, or comparing the resulting potential rate of coagulation with an equivalent rate determined for the plasma sample in the absence of activated exogenous protein C; and determining the functional activity of the free protein C from this comparison.
摘要翻译： PCT No.PCT / AU95 / 00474 Sec。 371日期1997年04月24日 102（e）日期1997年4月24日PCT提交1995年8月7日PCT公布。公开号WO96 / 04560 日期1996年2月15日人血浆样品中蛋白C的功能活性测定方法包括通过激活的外源蛋白C将人血浆样品与激活因子V的外源试剂和通过因子X的凝血机制的共同途径进行孵育以及用于有效凝固人血浆样品所必需的成分，或用活化的外源蛋白C以及有效成分所必需的成分，以以因子V依赖性方式诱导凝血酶存在的外源试剂孵育人血浆样品人血浆样品凝结; 监测指示血浆样品的潜在凝血速率的反应并将所得到的潜在凝血速率与正常患者的等效速率进行比较，或将所得到的潜在凝血速率与在不存在的血浆样品中测定的等效速率进行比较的活化外源蛋白C; 并从该比较中确定游离蛋白C的功能活性。

9. 发明授权

US5453370A Method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes 失效
标题翻译：从蛇毒中制备磷脂依赖性凝血酶原激活物的方法
公开(公告)号：US5453370A
公开(公告)日：1995-09-26
申请号：US983341
申请日：1992-11-30
申请人： Douglas A. Triplett , Kurt Stocker
发明人： Douglas A. Triplett , Kurt Stocker
IPC分类号： A61K35/58 , A61P7/04 , C07K14/46 , C12N9/64 , C12Q1/56 , G01N33/53 , C12N9/50 , C12N9/48
CPC分类号： C12Q1/56 , C07K14/46 , C12N9/6418 , G01N2333/4613 , G01N2333/4633 , G01N2333/4646 , G01N2405/04
摘要： A method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes belonging to the Elapidae family, the activator comprising an increased plasma clotting activity in the presence of phospholipids and calcium ions; a reduced activity in the presence of Lupus Anticoagulant; an ability to facilitate clotting in a normal clotting time in the presence of platelet poor plasma, the plasma having normal or decreased levels of factor V, VII, VIII, IX, or X; and a major band with a molecular weight of 40,000 to 60,000 daltons on an SDS gel.
摘要翻译：一种从属于Elapidae家族的蛇的毒液制备磷脂依赖性凝血酶原激活剂的方法，所述活化剂包括在磷脂和钙离子存在下增加的血浆凝血活性; 存在狼疮抗凝剂的活性降低; 在血小板不足等离子体存在下，在正常凝血时间促进凝血的能力，血浆具有正常或降低的因子V，VII，VIII，IX或X水平; 和SDS凝胶上分子量为40,000至60,000道尔顿的主要条带。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式